What are the best nasal decongestants for an otherwise healthy adult with an uncomplicated upper‑respiratory infection?

Best Nasal Decongestants for Uncomplicated Upper Respiratory Infection

For an otherwise healthy adult with an uncomplicated upper respiratory infection, topical oxymetazoline (0.05%) nasal spray provides the most rapid and effective relief of nasal congestion, but must be strictly limited to 3 days maximum to prevent rhinitis medicamentosa. 1

First-Line Recommendation: Short-Term Topical Decongestant

Topical oxymetazoline (0.05%) delivers superior efficacy compared to all other decongestant options, with onset of action within minutes and sustained relief for up to 12 hours after a single dose. 1, 2

• Apply 2 sprays per nostril twice daily for a maximum of 3 consecutive days 1
• Provides both statistically significant and clinically meaningful improvement in subjective nasal congestion scores and objective nasal airflow measurements 2
• Rebound congestion (rhinitis medicamentosa) can begin as early as day 3–4 of continuous use, making the 3-day limit critical 3, 1

Critical Safety Warning

Never exceed 3 days of topical decongestant use—rhinitis medicamentosa may develop by the third or fourth day of treatment. 3, 1

• If rhinitis medicamentosa develops, immediately discontinue the topical decongestant 1
• Intranasal corticosteroids should then be initiated to allow nasal mucosa recovery 3, 1

Second-Line Option: Oral Pseudoephedrine

If topical decongestants are contraindicated or the patient prefers oral therapy, pseudoephedrine 60 mg every 4–6 hours is the only oral decongestant with proven efficacy. 1, 4

• Pseudoephedrine reduces nasal congestion through α-adrenergic vasoconstriction with documented efficacy using objective measures of nasal airway resistance 4
• Oral phenylephrine should be avoided entirely—it undergoes extensive first-pass gut metabolism rendering it ineffective at standard doses 1, 4, 5
• Multiple-dose oral decongestants show only a small clinical effect (standardized mean difference 0.49) compared to placebo 6

Cardiovascular Precautions for Oral Decongestants

Use pseudoephedrine with extreme caution or avoid entirely in patients with arrhythmias, angina pectoris, coronary artery disease, cerebrovascular disease, uncontrolled hypertension, hyperthyroidism, bladder neck obstruction, or glaucoma. 1, 4

• Pseudoephedrine causes small increases in systolic blood pressure (0.99 mmHg) and heart rate (2.83 beats/min) 4
• Monitor blood pressure if prescribing to patients with controlled hypertension 1

Adjunctive Therapy: Nasal Saline Irrigation

Nasal saline irrigation provides additional symptomatic relief with minimal risk of adverse effects and should be recommended alongside any decongestant therapy. 1, 7

• Reduces symptom severity and may accelerate recovery in upper respiratory infections 7
• Can be used as monotherapy for patients who cannot tolerate pharmacologic decongestants 1

When to Consider Intranasal Corticosteroids Instead

For patients requiring ongoing treatment beyond 3 days, intranasal corticosteroids (e.g., mometasone furoate 200 µg twice daily) are the appropriate first-line therapy rather than continued decongestant use. 1

• Intranasal corticosteroids significantly improve nasal symptoms in post-viral acute rhinosinusitis compared to placebo, with greatest benefit observed after approximately 15 days of use 1
• Onset of action occurs within 12 hours, making them suitable for subacute congestion 1
• Treatment course should continue for 2–4 weeks for optimal symptom reduction 1

Common Pitfalls to Avoid

Do not recommend first-generation antihistamines (e.g., diphenhydramine, chlorpheniramine)—they produce marked sedation and anticholinergic effects without improving nasal congestion in viral upper respiratory infections. 3, 1

• Controlled trials demonstrate that antihistamine-decongestant combinations are not effective for upper respiratory infection symptoms 3
• Second-generation antihistamines are also less effective for nasal congestion than for other nasal symptoms 1

Avoid all over-the-counter cough and cold medications in children younger than 6 years due to lack of proven benefit and risk of toxicity. 3, 4

• Between 1969 and 2006, there were 54 fatalities associated with decongestants in children age ≤6 years, with 43 occurring in infants under 1 year 3

Expected Clinical Course

The majority of patients with viral upper respiratory infections experience symptomatic improvement within 7 days, and approximately 90% are cured or markedly improved by day 15. 1

• Instruct patients to seek medical review if symptoms worsen or persist beyond 2 weeks, as this may indicate progression to bacterial rhinosinusitis requiring alternative management 1